Daniel Geffken

Biography

 Mr. Daniel E. Geffken, also known as Dan, MBA, has been the Chief Financial Officer of ProMIS Neurosciences Inc. since March 22, 2017. Mr. Geffken has been an Interim Chief Financial Officer of Apellis Pharmaceuticals, Inc. since August 2015. He is the Founder of Danforth Advisors LLC and has been its Managing Director since October 2011. He serves as an Interim Chief Financial Officer at Stealth BioTherapeutics Incorporated. He serves as the Chief Financial Officer of Nemucore Medical Innovations, Inc. He served as an Interim Chief Financial Officer of Marina Biotech, Inc. from May 13, 2014 to October 31, 2016. He served as Principal Financial Officer and Senior Financial Consultant at Gelesis, Inc. He served as an Interim Chief Financial Officer of Novira Therapeutics, Inc. He served as the Chief Operating Officer of Seaside Therapeutics, LLC from October 14, 2009 to 2011 and also served as its Chief Financial Officer. He served as the Chief Financial Officer of seven companies, ranging from venture-backed start-ups to publicly-held corporations. He served as the Chief Financial Officer of Codon Devices, Inc. since March 21, 2007 and also served as its Senior Vice President. He joined Codon Devices in March 2007. He served as the Chief Financial Officer and Executive Vice President of Konarka Technologies, Inc. from August 2006 to March 2007 and served as its Vice President. He has more than 25 years of financial management experience in the life sciences industry. He served as the Chief Financial Officer and Senior Vice President of Business Development of OmniSonics Medical Technologies, Inc. from December 2003 to August 2006. He joined Omnisonics in December of 2003. He served as the Chief Financial Officer and Vice President of CytoTherapeutics, Inc. He served as the Chief Financial Officer and Treasurer of Shire Human Genetic Therapies, Inc. (also known as Transkaryotic Therapies Inc.) from February 1997 to April 18, 2003 and its Senior Vice President of Finance from December 2000 to April 18, 2003. He served as Vice President of Finance of Transkaryotic Therapies Inc. from February 1997 to December 2000. He held a variety of senior financial roles at Anderson Group (now Moscow CableCom Corp.) and Medchem Products (now C. R. Bard Inc.). He served as a Principal in a private equity firm and was a Certified Public Accountant (CPA) at KPMG. He spent several years at KPMG. He has been a Director at Alcobra Ltd., since May 2013. He has been an Independent Director of Cyberkinetics Neurotechnology Systems Inc. since January 2005. Mr. Geffken received his Bachelor of Science Degree in Economics from The Wharton School at the University of Pennsylvania in 1979 and his MBA from The Harvard Business School in 1987.

Research Interest

 Life science industry, finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property, and manufacturing functions.